Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Oct 23, 2024 12:11pm
193 Views
Post# 36278698

California Conference

California ConferenceWell today marks conference number 1 that Arch is attending. I errored in my previous post stating they were presenting, in fact they are simply attending but hopefully networking aggressively. That may seem unimportant but keep in mind we are 8 months into dosing at 5 sites in Turkey plus soon to start the Pontiac trial. This is out of the norm for the frugal Arch management team to attend these types of conference, where there is smoke, generally there is fire.

The conference in Stockholm in November is more interesting in my point of view as Arch is in fact presenting to a target rich environment. Will they be sharing new data???? I am sure many of the people in attendence today in California will also be attending in November to the Stockholm conference.

Arch is currently up 36% over the past 3 months and up 21% the past 30 days. We are 8 months into dosing and I would suggest the markets are starting to signal something big is brewing!

All the best to the longs!!!
<< Previous
Bullboard Posts
Next >>